PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse

BACKGROUND: Immune checkpoint inhibitors have led to a breakthrough in solid tumor immunotherapy, but related studies on musculoskeletal tumors are few, especially for PD-L2. METHODS: We examined expression of three molecular effectors of the PD-1 axis in 234 patients with musculoskeletal tumors, in...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Bingxin, Ren, Tingting, Huang, Yi, Sun, Kunkun, Wang, Shidong, Bao, Xing, Liu, Kuisheng, Guo, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801803/
https://www.ncbi.nlm.nih.gov/pubmed/29409495
http://dx.doi.org/10.1186/s13045-018-0560-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801803/
https://www.ncbi.nlm.nih.gov/pubmed/29409495
http://dx.doi.org/10.1186/s13045-018-0560-1

Ejemplares similares